Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update

Posted by on Aug 14th, 2023

Anika Therapeutics, Inc. (NASDAQ:ANIK – Get Free Report) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 489,800 shares, an increase of 13.6% from the July 15th total of 431,100 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 83,800 shares, the short-interest ratio is presently 5.8 days.

Analyst Ratings Changes

ANIK has been the subject of a number of research reports. StockNews.com assumed coverage on shares of Anika Therapeutics in a research report on Thursday, May 18th. They set a “hold” rating for the company. Stephens lowered their price target on shares of Anika Therapeutics from $28.00 to $23.00 and set an “equal weight” rating for the company in a report on Thursday.

View Our Latest Stock Report on Anika Therapeutics

Anika Therapeutics Stock Down 1.1 %

ANIK opened at $18.38 on Monday. Anika Therapeutics has a 52-week low of $18.21 and a 52-week high of $32.51. The company has a 50 day moving average of $25.01 and a two-hundred day moving average of $27.08. The company has a market cap of $268.90 million, a P/E ratio of -12.01 and a beta of 0.75.

Institutional Investors Weigh In On Anika Therapeutics

Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its stake in Anika Therapeutics by 61.2% during the third quarter. Tower Research Capital LLC TRC now owns 1,601 shares of the biotechnology company’s stock worth $38,000 after buying an additional 608 shares during the period. Altshuler Shaham Ltd acquired a new position in shares of Anika Therapeutics during the fourth quarter worth $58,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Anika Therapeutics during the third quarter worth $84,000. UBS Group AG lifted its position in shares of Anika Therapeutics by 16.6% during the third quarter. UBS Group AG now owns 5,781 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 825 shares in the last quarter. Finally, Louisiana State Employees Retirement System acquired a new position in shares of Anika Therapeutics during the second quarter worth $200,000. 88.25% of the stock is currently owned by hedge funds and other institutional investors.

About Anika Therapeutics

(Get Free Report)

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.

Featured Stories

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.